Pfizer ordered to pay $142.1 million for marketing Neurontin for unapproved uses in the US

A US district court judge upheld a jury award in a case that alleged that Pfizer improperly marketed its epilepsy drug Neurontin and tripled the original award to $142.1 million under a provision of the federal Racketeer Influenced and Corrupt Organizations Act. In her decision, Judge Patti Saris agreed with the jury's finding that Kaiser Foundation Health Plan and Kaiser Foundation Hospitals deserved the award because they were led to believe that the drug could also be used to treat migraines and bipolar disorder.

Pfizer spokesman Chris Loder said the company was pleased with Saris’ decision to deny Kaiser’s bid for pre- judgment interest totalling $76 million on the award. "As we maintained all along, Pfizer has strong defences in this case and intends to appeal," he remarked.

Pfizer currently faces more than 300 suits related to the promotion of Neurontin for unapproved uses or for not disclosing the drug's health risks.

To read more Top Story articles, click here.